The amelioration of LPS induced lung inflammation following CXCL10 neutralisation in rats, and the proposition of anti‐TNFα therapy in COVID‐19 patients, therefore highlights the potential for combining SARS‐CoV‐2 infections with TNFα and CXCL10 challenge as a further method in the development of models with a more severe phenotype. This evidence concerns the gene CXCL10 and COVID-19.